Clinical Trials

Blue Faery: The Adrienne Wilson Liver Cancer Association



Clinical Trials

Print Friendly, PDF & Email

Clinical trials are studies conducted on volunteers using investigational treatments or methods. The decision to enroll in a trial should be based on concrete information and eligibility depends on many factors. For more information about HCC clinical trials in your area, visit

  • Discuss the advantages, disadvantages and side effects of treatment options with your doctor.
  • Ask your doctor about the possibility of using experimental therapies and eligibility to participate in clinical trials. If you want to participate in clinical trial, ask what is the phase of the trial.
  • Consider seeking a second opinion if your health insurance allows you the option to do so.

Liver Cancer Clinical Trials (featured listings)

The following clinical trials are paid listings. Blue Faery does not endorse, sponsor or recommend any specific clinical trial. 

A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma*

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.

Condition: Hepatocellular carcinoma
Intervention: CVM-1118
Phase: Phase 2
Study Type: Interventional
Study Design: Single Group Assignment, Open Label
Primary Purpose: Treatment

For more information, email

Kirsten Dorr, Senior Project Manager
Cell Phone: (858) 337-2927

SciQuus Oncology Inc.
4250 Executive Square, Suite 450
La Jolla, CA 92037
United States
Map It
Business Phone: (858) 642-0386

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma*

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527 (Part 1), and to assess the safety and tolerability of H3B-6527 as a single agent administered orally (Part 2) in participants with advanced hepatocellular carcinoma (HCC).

Condition: Hepatocellular carcinoma
Intervention: Dose Escalation
Phase: Phase 1
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Objective tumor response

For more information, email

H3 Biomedicine with Eisai Inc
300 Technology Square, 5th Floor
Cambridge, MA 02139
United States
Map It
Business Phone: (888) 274-2378

*Indicates a paid listing

Scroll Up